APO Research
Talk to an analyst

APO RESEARCH · REPORT

C-MET & HGF Inhibitors

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

Selected research

Market Structure

Global C-MET & HGF Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

28 December 2025191 pages

Choose your research edition.

Industry ResearchC-MET & HGF Inhibitors Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal C-MET & HGF Inhibitors Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal C-MET & HGF Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal C-MET & HGF Inhibitors Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal C-MET & HGF Inhibitors Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

c-Met inhibitors are a class of small molecules that inhibit the enzymatic activity of the c-Met tyrosine kinase, the receptor of hepatocyte growth factor/scatter factor (HGF/SF).

There are three kinds of C-MET / HGF Inhibitors, which are Cabozantinib, Crizotinib and Others. Cabozantinib hold the largest share of the C-MET / HGF Inhibitors market, with a revenue market share nearly 66% in 2019.

C-MET / HGF Inhibitors is sold through Hospitals and Drugs Store. The most proportion of C-MET / HGF Inhibitors is sold through Hospitals, and the market share in 2019 is about 77%.

Read the full market overview

North America is the largest consumption place, with a consumption market share nearly 60% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of about 34%.

Shandong Exelixis, Ipsen, Pfizer, etc. are the leader of the industry, and top 3 players hold about 100% revenue market share.

This report provides an overview of the global C-MET & HGF Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of C-MET & HGF Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents C-MET & HGF Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the C-MET & HGF Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

C-MET & HGF Inhibitors Segment by Company

Exelixis

Ipsen

Pfizer

Novartis

Takeda

Merck KGaA

Merck

Daiichi Sankyo

GSK

Bristol-Myers Squibb(BMS)

Roche

AVEO Pharmaceuticals

Amgen

AstraZeneca

Mirati Therapeutics

Eli Lilly

Johnson & Johnson

Eisai

Hutchison MediPharma

Kringle Pharmaceuticals

C-MET & HGF Inhibitors Segment by Type

Cabozantinib

Crizotinib

Others

C-MET & HGF Inhibitors Segment by Application

Hospital

Drug Store

C-MET & HGF Inhibitors Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global C-MET & HGF Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of C-MET & HGF Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of C-MET & HGF Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the C-MET & HGF Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of C-MET & HGF Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of C-MET & HGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of C-MET & HGF Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. C-MET & HGF Inhibitors Industry Trends Table 2. C-MET & HGF Inhibitors Industry Drivers Table 3. C-MET & HGF Inhibitors Industry Opportunities and Challenges Table 4. C-MET & HGF Inhibitors Industry Restraints Table 5. Global C-MET & HGF Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global C-MET & HGF Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global C-MET & HGF Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global C-MET & HGF Inhibitors Sales Market Share by Manufacturers Table 9. Global C-MET & HGF Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global C-MET & HGF Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global C-MET & HGF Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global C-MET & HGF Inhibitors Manufacturers, Product Type & Application Table 13. Global C-MET & HGF Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global C-MET & HGF Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Cabozantinib Table 17. Major Manufacturers of Crizotinib Table 18. Major Manufacturers of Others Table 19. Global C-MET & HGF Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global C-MET & HGF Inhibitors Sales by Type (2021-2026) & (K Units) Table 21. Global C-MET & HGF Inhibitors Sales by Type (2027-2032) & (K Units) Table 22. Global C-MET & HGF Inhibitors Sales Market Share by Type (2021-2026) Table 23. Global C-MET & HGF Inhibitors Sales Market Share by Type (2027-2032) Table 24. Global C-MET & HGF Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 25. Global C-MET & HGF Inhibitors Revenue by Type (2021-2026) & (K Units) Table 26. Global C-MET & HGF Inhibitors Revenue by Type (2027-2032) & (K Units) Table 27. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2021-2026) Table 28. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2027-2032) Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Drug Store Table 31. Global C-MET & HGF Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global C-MET & HGF Inhibitors Sales by Application (2021-2026) & (K Units) Table 33. Global C-MET & HGF Inhibitors Sales by Application (2027-2032) & (K Units) Table 34. Global C-MET & HGF Inhibitors Sales Market Share by Application (2021-2026) Table 35. Global C-MET & HGF Inhibitors Sales Market Share by Application (2027-2032) Table 36. Global C-MET & HGF Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global C-MET & HGF Inhibitors Revenue by Application (2021-2026) & (K Units) Table 38. Global C-MET & HGF Inhibitors Revenue by Application (2027-2032) & (K Units) Table 39. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2021-2026) Table 40. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2027-2032) Table 41. Global C-MET & HGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global C-MET & HGF Inhibitors Sales by Region (2021-2026) & (K Units) Table 43. Global C-MET & HGF Inhibitors Sales Market Share by Region (2021-2026) Table 44. Global C-MET & HGF Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global C-MET & HGF Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 46. North America C-MET & HGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 48. North America C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 49. Europe C-MET & HGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 51. Europe C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific C-MET & HGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa C-MET & HGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2027-2032) & (K Units) Table 58. Global C-MET & HGF Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global C-MET & HGF Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 60. Global C-MET & HGF Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 61. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2021-2026) Table 62. Global C-MET & HGF Inhibitors Revenue Market Share by Region (2027-2032) Table 63. Exelixis Company Information Table 64. Exelixis Business Overview Table 65. Exelixis C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Exelixis C-MET & HGF Inhibitors Product Portfolio Table 67. Exelixis Recent Development Table 68. Ipsen Company Information Table 69. Ipsen Business Overview Table 70. Ipsen C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Ipsen C-MET & HGF Inhibitors Product Portfolio Table 72. Ipsen Recent Development Table 73. Pfizer Company Information Table 74. Pfizer Business Overview Table 75. Pfizer C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Pfizer C-MET & HGF Inhibitors Product Portfolio Table 77. Pfizer Recent Development Table 78. Novartis Company Information Table 79. Novartis Business Overview Table 80. Novartis C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Novartis C-MET & HGF Inhibitors Product Portfolio Table 82. Novartis Recent Development Table 83. Takeda Company Information Table 84. Takeda Business Overview Table 85. Takeda C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Takeda C-MET & HGF Inhibitors Product Portfolio Table 87. Takeda Recent Development Table 88. Merck KGaA Company Information Table 89. Merck KGaA Business Overview Table 90. Merck KGaA C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Merck KGaA C-MET & HGF Inhibitors Product Portfolio Table 92. Merck KGaA Recent Development Table 93. Merck Company Information Table 94. Merck Business Overview Table 95. Merck C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Merck C-MET & HGF Inhibitors Product Portfolio Table 97. Merck Recent Development Table 98. Daiichi Sankyo Company Information Table 99. Daiichi Sankyo Business Overview Table 100. Daiichi Sankyo C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio Table 102. Daiichi Sankyo Recent Development Table 103. GSK Company Information Table 104. GSK Business Overview Table 105. GSK C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. GSK C-MET & HGF Inhibitors Product Portfolio Table 107. GSK Recent Development Table 108. Bristol-Myers Squibb(BMS) Company Information Table 109. Bristol-Myers Squibb(BMS) Business Overview Table 110. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio Table 112. Bristol-Myers Squibb(BMS) Recent Development Table 113. Roche Company Information Table 114. Roche Business Overview Table 115. Roche C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. Roche C-MET & HGF Inhibitors Product Portfolio Table 117. Roche Recent Development Table 118. AVEO Pharmaceuticals Company Information Table 119. AVEO Pharmaceuticals Business Overview Table 120. AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio Table 122. AVEO Pharmaceuticals Recent Development Table 123. Amgen Company Information Table 124. Amgen Business Overview Table 125. Amgen C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Amgen C-MET & HGF Inhibitors Product Portfolio Table 127. Amgen Recent Development Table 128. AstraZeneca Company Information Table 129. AstraZeneca Business Overview Table 130. AstraZeneca C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. AstraZeneca C-MET & HGF Inhibitors Product Portfolio Table 132. AstraZeneca Recent Development Table 133. Mirati Therapeutics Company Information Table 134. Mirati Therapeutics Business Overview Table 135. Mirati Therapeutics C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio Table 137. Mirati Therapeutics Recent Development Table 138. Eli Lilly Company Information Table 139. Eli Lilly Business Overview Table 140. Eli Lilly C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. Eli Lilly C-MET & HGF Inhibitors Product Portfolio Table 142. Eli Lilly Recent Development Table 143. Johnson & Johnson Company Information Table 144. Johnson & Johnson Business Overview Table 145. Johnson & Johnson C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 146. Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio Table 147. Johnson & Johnson Recent Development Table 148. Eisai Company Information Table 149. Eisai Business Overview Table 150. Eisai C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 151. Eisai C-MET & HGF Inhibitors Product Portfolio Table 152. Eisai Recent Development Table 153. Hutchison MediPharma Company Information Table 154. Hutchison MediPharma Business Overview Table 155. Hutchison MediPharma C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 156. Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio Table 157. Hutchison MediPharma Recent Development Table 158. Kringle Pharmaceuticals Company Information Table 159. Kringle Pharmaceuticals Business Overview Table 160. Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 161. Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio Table 162. Kringle Pharmaceuticals Recent Development Table 163. Key Raw Materials Table 164. Raw Materials Key Suppliers Table 165. C-MET & HGF Inhibitors Distributors List Table 166. C-MET & HGF Inhibitors Customers List Table 167. Research Programs/Design for This Report Table 168. Authors List of This Report Table 169. Secondary Sources Table 170. Primary Sources List of Figures Figure 1. C-MET & HGF Inhibitors Product Image Figure 2. Global C-MET & HGF Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global C-MET & HGF Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global C-MET & HGF Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global C-MET & HGF Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 C-MET & HGF Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Cabozantinib Image Figure 9. Crizotinib Image Figure 10. Others Image Figure 11. Global C-MET & HGF Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global C-MET & HGF Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 13. Global C-MET & HGF Inhibitors Sales Market Share by Type (2021-2032) Figure 14. Global C-MET & HGF Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global C-MET & HGF Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 16. Global C-MET & HGF Inhibitors Revenue Market Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Drug Store Image Figure 19. Global C-MET & HGF Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global C-MET & HGF Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global C-MET & HGF Inhibitors Sales Market Share by Application (2021-2032) Figure 22. Global C-MET & HGF Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global C-MET & HGF Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global C-MET & HGF Inhibitors Revenue Market Share by Application (2021-2032) Figure 25. North America C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America C-MET & HGF Inhibitors Sales Market Share by Country (2021-2032) Figure 27. U.S. C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe C-MET & HGF Inhibitors Sales Market Share by Country (2021-2032) Figure 32. Germany C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific C-MET & HGF Inhibitors Sales Market Share by Country (2021-2032) Figure 39. China C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa C-MET & HGF Inhibitors Sales Market Share by Country (2021-2032) Figure 47. Brazil C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile C-MET & HGF Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global C-MET & HGF Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global C-MET & HGF Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Figure 58. North America C-MET & HGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. Europe C-MET & HGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific C-MET & HGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa C-MET & HGF Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa C-MET & HGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. C-MET & HGF Inhibitors Value Chain Figure 66. Manufacturing Cost Structure Figure 67. C-MET & HGF Inhibitors Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Cabozantinib
  • Crizotinib
  • Others
Applications
  • Hospital
  • Drug Store
Companies covered
  • Exelixis
  • Ipsen
  • Pfizer
  • Novartis
  • Takeda
  • Merck KGaA
  • Merck
  • Daiichi Sankyo
  • GSK
  • Bristol-Myers Squibb(BMS)
  • Roche
  • AVEO Pharmaceuticals
  • Amgen
  • AstraZeneca
  • Mirati Therapeutics
  • Eli Lilly
  • Johnson & Johnson
  • Eisai
  • Hutchison MediPharma
  • Kringle Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global C-MET & HGF Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global C-MET & HGF Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global C-MET & HGF Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global C-MET & HGF Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global C-MET & HGF Inhibitors Market Dynamics
  1. 2.1 C-MET & HGF Inhibitors Industry Trends
  2. 2.2 C-MET & HGF Inhibitors Industry Drivers
  3. 2.3 C-MET & HGF Inhibitors Industry Opportunities and Challenges
  4. 2.4 C-MET & HGF Inhibitors Industry Restraints
3 C-MET & HGF Inhibitors Market by Manufacturers
  1. 3.1 Global C-MET & HGF Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global C-MET & HGF Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global C-MET & HGF Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global C-MET & HGF Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global C-MET & HGF Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global C-MET & HGF Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global C-MET & HGF Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global C-MET & HGF Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 C-MET & HGF Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 C-MET & HGF Inhibitors Tier 1, Tier 2, and Tier 3
4 C-MET & HGF Inhibitors Market by Type
  1. 4.1 C-MET & HGF Inhibitors Type Introduction
  2. 4.1.1 Cabozantinib
  3. 4.1.2 Crizotinib
  4. 4.1.3 Others
  5. 4.2 Global C-MET & HGF Inhibitors Sales by Type
  6. 4.2.1 Global C-MET & HGF Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global C-MET & HGF Inhibitors Sales by Type (2021-2032)
  8. 4.2.3 Global C-MET & HGF Inhibitors Sales Market Share by Type (2021-2032)
  9. 4.3 Global C-MET & HGF Inhibitors Revenue by Type
  10. 4.3.1 Global C-MET & HGF Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global C-MET & HGF Inhibitors Revenue by Type (2021-2032)
  12. 4.3.3 Global C-MET & HGF Inhibitors Revenue Market Share by Type (2021-2032)
5 C-MET & HGF Inhibitors Market by Application
  1. 5.1 C-MET & HGF Inhibitors Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Drug Store
  4. 5.2 Global C-MET & HGF Inhibitors Sales by Application
  5. 5.2.1 Global C-MET & HGF Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global C-MET & HGF Inhibitors Sales by Application (2021-2032)
  7. 5.2.3 Global C-MET & HGF Inhibitors Sales Market Share by Application (2021-2032)
  8. 5.3 Global C-MET & HGF Inhibitors Revenue by Application
  9. 5.3.1 Global C-MET & HGF Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global C-MET & HGF Inhibitors Revenue by Application (2021-2032)
  11. 5.3.3 Global C-MET & HGF Inhibitors Revenue Market Share by Application (2021-2032)
6 Global C-MET & HGF Inhibitors Sales by Region
  1. 6.1 Global C-MET & HGF Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global C-MET & HGF Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global C-MET & HGF Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global C-MET & HGF Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America C-MET & HGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America C-MET & HGF Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe C-MET & HGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe C-MET & HGF Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific C-MET & HGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific C-MET & HGF Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa C-MET & HGF Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa C-MET & HGF Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global C-MET & HGF Inhibitors Revenue by Region
  1. 7.1 Global C-MET & HGF Inhibitors Revenue by Region
  2. 7.1.1 Global C-MET & HGF Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global C-MET & HGF Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global C-MET & HGF Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global C-MET & HGF Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America C-MET & HGF Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America C-MET & HGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe C-MET & HGF Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe C-MET & HGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific C-MET & HGF Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific C-MET & HGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa C-MET & HGF Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa C-MET & HGF Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Exelixis
  2. 8.1.1 Exelixis Company Information
  3. 8.1.2 Exelixis Business Overview
  4. 8.1.3 Exelixis C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Exelixis C-MET & HGF Inhibitors Product Portfolio
  6. 8.1.5 Exelixis Recent Developments
  7. 8.2 Ipsen
  8. 8.2.1 Ipsen Company Information
  9. 8.2.2 Ipsen Business Overview
  10. 8.2.3 Ipsen C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ipsen C-MET & HGF Inhibitors Product Portfolio
  12. 8.2.5 Ipsen Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer C-MET & HGF Inhibitors Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 Novartis
  20. 8.4.1 Novartis Company Information
  21. 8.4.2 Novartis Business Overview
  22. 8.4.3 Novartis C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Novartis C-MET & HGF Inhibitors Product Portfolio
  24. 8.4.5 Novartis Recent Developments
  25. 8.5 Takeda
  26. 8.5.1 Takeda Company Information
  27. 8.5.2 Takeda Business Overview
  28. 8.5.3 Takeda C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Takeda C-MET & HGF Inhibitors Product Portfolio
  30. 8.5.5 Takeda Recent Developments
  31. 8.6 Merck KGaA
  32. 8.6.1 Merck KGaA Company Information
  33. 8.6.2 Merck KGaA Business Overview
  34. 8.6.3 Merck KGaA C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck KGaA C-MET & HGF Inhibitors Product Portfolio
  36. 8.6.5 Merck KGaA Recent Developments
  37. 8.7 Merck
  38. 8.7.1 Merck Company Information
  39. 8.7.2 Merck Business Overview
  40. 8.7.3 Merck C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Merck C-MET & HGF Inhibitors Product Portfolio
  42. 8.7.5 Merck Recent Developments
  43. 8.8 Daiichi Sankyo
  44. 8.8.1 Daiichi Sankyo Company Information
  45. 8.8.2 Daiichi Sankyo Business Overview
  46. 8.8.3 Daiichi Sankyo C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Daiichi Sankyo C-MET & HGF Inhibitors Product Portfolio
  48. 8.8.5 Daiichi Sankyo Recent Developments
  49. 8.9 GSK
  50. 8.9.1 GSK Company Information
  51. 8.9.2 GSK Business Overview
  52. 8.9.3 GSK C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GSK C-MET & HGF Inhibitors Product Portfolio
  54. 8.9.5 GSK Recent Developments
  55. 8.10 Bristol-Myers Squibb(BMS)
  56. 8.10.1 Bristol-Myers Squibb(BMS) Company Information
  57. 8.10.2 Bristol-Myers Squibb(BMS) Business Overview
  58. 8.10.3 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bristol-Myers Squibb(BMS) C-MET & HGF Inhibitors Product Portfolio
  60. 8.10.5 Bristol-Myers Squibb(BMS) Recent Developments
  61. 8.11 Roche
  62. 8.11.1 Roche Company Information
  63. 8.11.2 Roche Business Overview
  64. 8.11.3 Roche C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Roche C-MET & HGF Inhibitors Product Portfolio
  66. 8.11.5 Roche Recent Developments
  67. 8.12 AVEO Pharmaceuticals
  68. 8.12.1 AVEO Pharmaceuticals Company Information
  69. 8.12.2 AVEO Pharmaceuticals Business Overview
  70. 8.12.3 AVEO Pharmaceuticals C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 AVEO Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
  72. 8.12.5 AVEO Pharmaceuticals Recent Developments
  73. 8.13 Amgen
  74. 8.13.1 Amgen Company Information
  75. 8.13.2 Amgen Business Overview
  76. 8.13.3 Amgen C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Amgen C-MET & HGF Inhibitors Product Portfolio
  78. 8.13.5 Amgen Recent Developments
  79. 8.14 AstraZeneca
  80. 8.14.1 AstraZeneca Company Information
  81. 8.14.2 AstraZeneca Business Overview
  82. 8.14.3 AstraZeneca C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AstraZeneca C-MET & HGF Inhibitors Product Portfolio
  84. 8.14.5 AstraZeneca Recent Developments
  85. 8.15 Mirati Therapeutics
  86. 8.15.1 Mirati Therapeutics Company Information
  87. 8.15.2 Mirati Therapeutics Business Overview
  88. 8.15.3 Mirati Therapeutics C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Mirati Therapeutics C-MET & HGF Inhibitors Product Portfolio
  90. 8.15.5 Mirati Therapeutics Recent Developments
  91. 8.16 Eli Lilly
  92. 8.16.1 Eli Lilly Company Information
  93. 8.16.2 Eli Lilly Business Overview
  94. 8.16.3 Eli Lilly C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Eli Lilly C-MET & HGF Inhibitors Product Portfolio
  96. 8.16.5 Eli Lilly Recent Developments
  97. 8.17 Johnson & Johnson
  98. 8.17.1 Johnson & Johnson Company Information
  99. 8.17.2 Johnson & Johnson Business Overview
  100. 8.17.3 Johnson & Johnson C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Johnson & Johnson C-MET & HGF Inhibitors Product Portfolio
  102. 8.17.5 Johnson & Johnson Recent Developments
  103. 8.18 Eisai
  104. 8.18.1 Eisai Company Information
  105. 8.18.2 Eisai Business Overview
  106. 8.18.3 Eisai C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Eisai C-MET & HGF Inhibitors Product Portfolio
  108. 8.18.5 Eisai Recent Developments
  109. 8.19 Hutchison MediPharma
  110. 8.19.1 Hutchison MediPharma Company Information
  111. 8.19.2 Hutchison MediPharma Business Overview
  112. 8.19.3 Hutchison MediPharma C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Hutchison MediPharma C-MET & HGF Inhibitors Product Portfolio
  114. 8.19.5 Hutchison MediPharma Recent Developments
  115. 8.20 Kringle Pharmaceuticals
  116. 8.20.1 Kringle Pharmaceuticals Company Information
  117. 8.20.2 Kringle Pharmaceuticals Business Overview
  118. 8.20.3 Kringle Pharmaceuticals C-MET & HGF Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Kringle Pharmaceuticals C-MET & HGF Inhibitors Product Portfolio
  120. 8.20.5 Kringle Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 C-MET & HGF Inhibitors Value Chain Analysis
  2. 9.1.1 C-MET & HGF Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 C-MET & HGF Inhibitors Production Mode & Process
  6. 9.2 C-MET & HGF Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 C-MET & HGF Inhibitors Distributors
  9. 9.2.3 C-MET & HGF Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst